Vivex Biologics, Inc. Completes Subject Enrollment for its ASCEND Trial Evaluating VIA Disc NP™ for Symptomatic Disc Degeneration
OrthoSpineNews
JULY 29, 2025
Data readout expected in Q1 2026 MIAMI, July 29, 2025 (GLOBE NEWSWIRE) — Vivex Biologics, Inc., Data from the trial are expected in the first quarter of 2026. “We Current interventions include physical therapy, anti-inflammatory medications, opioids, and spinal surgery.
Let's personalize your content